Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.6.2735

Clinical Significance of Basal-like Breast Cancer in Chinese Women in Heilongjiang Province  

Liu, Ying (Department of Oncology, Second Affiliated Hospital of Harbin Medical University)
Jiang, Qiu-Ying (Department of Oncology, Second Affiliated Hospital of Harbin Medical University)
Xin, Tao (Department of Oncology, Second Affiliated Hospital of Harbin Medical University)
Cai, Li (Department of Oncology, Affiliated Oncology Hospital of Harbin Medical University)
Zhao, Chang-Hong (Department of Oncology, Affiliated Oncology Hospital of Harbin Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.6, 2012 , pp. 2735-2738 More about this Journal
Abstract
Background: Our objective was to clarify the clinical and biological characteristics of basal-like breast cancer (BLBC) and non-basal-like breast cancer (TN3BKE) in Heilongjiang. Methods: We examined, by immunohistochemistry, expression of biological markers cytokeratin (CK) 5/6 and epidermal growth factor receptor (EGFR) and B cell specific moloney murine leukemia virus integration site 1( Bmi-1) in triple-negative breast cancer (TNBC). We studied the correlation between BLBC and several factors related to tumor progression, along with its prognostic value. Results: In the 229 cases of operable TNBC, BLBC was detected in 178 (77.7%) and TN3BKE- in 51 (22.2%). There was no significant difference in clinicopathological factors between them, However, BLBC was significantly associated with Bmi-1 expression (P=0.000) and shorter disease-free survival (DFS) (P = 0.045) and overall survival (OS) (P = 0.041). Conclusions: Compared with the non-basal group, patients with BLBC have a high expression of Bmi-1 and a poor prognosis.
Keywords
Basal like; breast cancer; prognosis;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 EmadA Rakha, SomaiaE Elsheikh, MuhammedA Aleskandarany, et al (2009). Triple-Negative Breast Cancer: Distinguishing between Basal and Non-basal Subtypes. Clin Cancer Res, 15, April1.
2 Foulkes WD, Stefansson IM, Chappuis PO, et al (2003). Germ line BRCA1 mutations and a basal epithelialphe-no type in breast cancer. J Natl Cancer Inst, 95, 1482-5.   DOI   ScienceOn
3 Goldhirsch A, Wood WC, Gelber RD, et al (2003). Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol, 21, 3357-65.   DOI   ScienceOn
4 Kobayashi S (2008). Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance. Breast Cancer, 15, 153-8.   DOI
5 Lakhani SR, Reis-Filho JS, Fulford L, et al (2005). Prediction of BRCA1 status inpatients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res, 11, 5175-80.   DOI
6 Livasy CA, Perou CM, Karaca G, et al (2007). Identification of a basal-like subtype of breast ductal carcinoma insitu. HumPathol, 38, 197-204.
7 Sorlie T, Tibshirani R, Parker J, et al (2003). Repeated observation of breast tumor subtypes in independent gene expression datasets. Proc Natl Acad Sci USA, 100, 8418-23.   DOI
8 Sotiriou C, Neo SY, McShane LM, et al (2003). Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA, 100, 10393-8.   DOI
9 Tan DS, Marchio C, Jones RL, et al (2008). Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat, 111, 27-44.   DOI
10 Tischkowitz M, Brunet JS, Begin LR, et al (2007). Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer, 7, 134.   DOI
11 Wang Y, Zhe H, Ding Z, Gao P, Zhang N, Li G (2012). Cancer stem cell marker Bmi-1 expression is associated with basallike phenotype and poor survival in breast cancer. World J Surg, 36, 1189-94.   DOI
12 Carey LA, Perou CM, Livasy CA, et al (2006). Race, breast cancer subtypes, and survival in the Carolina Breast CancerStudy. JAMA, 295, 2492-502.   DOI   ScienceOn
13 Xu Z, Liu H, Lv X, et al (2011). Knockdown of the Bmi-1 oncogene inhibits cell proliferation and induces cell apoptosis and is involved in the decrease of Akt phosphorylation in the human breast carcinoma cell line MCF-7. Oncol Rep, 25, 409-18.
14 Yamamoto Y, Ibusuki M, Nakano M, et al (2009). Clinical significance of basal-like subtype in triple-negative breast cancer. Breast Cancer, 16, 260-7.   DOI
15 Arnes JB, Collett K, Akslen LA, et al (2008). Independent prognostic value of the basal-like phenotype of breast cancer and associations with EGFR and candidate stem cell marker BMI-1. Histopathology, 52, 370-80.   DOI
16 Bidard FC, Conforti R, Boulet T, et al (2007).negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triplenegative' breast cancers. Ann Oncol, 18, 1285-6.   DOI   ScienceOn
17 Brady-West DC, McGrowder DA (2011). Triple negative breast cancer: therapeutic and prognostic implications. Asian Pac J Cancer Prev, 12, 2139-43.
18 Cheang MC, Voduc D, Bajdik C, et al (2008). Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res, 14, 1368-76.   DOI
19 Chuthapisith S, Permsapaya W, Warnnissorn M, et al (2012). Breast cancer subtypes identified by the ER, PR and HER-2 status in Thai women. Asian Pac J Cancer Prev, 13, 459-62.   DOI   ScienceOn
20 Matos I, Dufloth R, Alvarenga M, er al (2005). p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch, 447, 688-94.   DOI
21 Nielsen TO, Hsu FD, Jensen K, et al (2004). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res, 10, 5367-74.   DOI   ScienceOn
22 Perou CM, Sorlie T, Eisen MB, et al (2000). Molecular portraits of human breast tumors. Nature, 406, 747-52.   DOI   ScienceOn
23 Rakha EA, El-Sayed ME, Green AR, et al (2007). Prognostic markers in triple-negative breast cancer. Cancer, 109, 25-32.   DOI   ScienceOn
24 Sasa M, Bando Y, Takahashi M, et al (2008). Screening for basal marker expression is necessary or decision of therapeutic strategy for triple-negative breast cancer. J Surg Oncol, 97, 30-4.   DOI
25 Shipitsin M, Campbell LL, Argani P, et al (2007). Molecular definition of breast tumor heterogeneity. Cancer Cell, 11, 259-73.   DOI
26 Sorlie T, Perou CM, Tibshirani R, et al (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA, 98, 10869-74.   DOI   ScienceOn